 "Natco Pharma, Natco")
Natco Pharma on Tuesday said its consolidated net profit jumped 83 per cent on-year to Rs 676 crore in the September 2024 quarter, aided by robust sales.
The drug maker reported a net profit of Rs 369 crore in the July-September period of last fiscal.
Revenue from operations rose to Rs 1,371 crore as compared with Rs 1,031 crore in the year-ago period, the company said in a regulatory filing.
"The company has shown continued strong growth during the second quarter driven by exports formulation business and stable domestic pharmaceutical business," it stated.
The company said its board has declared a second interim dividend of Rs 1.5 per equity share of Rs 2 each for financial year 2024-25.
Shares of the drug firm ended 0.19 per cent down at Rs 1,393.15 apiece on the BSE.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
 "drugs, pharma sector")
 "Pharma companies step up use of advanced technologies to improve processes medical technology")
 "With Karnataka-based contract manufacturer Aequs Group now part of the Apple Inc supply chain, the American tech giant's Indian footprint is growing rapidly. According to data intelligence firm The Trade Vision (TTV), India has already emerged as the")
 "The aspirations of a young India and increased income levels have encouraged companies to consider mergers and acquisitions (M&A) to keep up with demand. In a world where consumer preferences change dramatically, M&As provide companies the means to r")
 "The Securities and Exchange Board of India (Sebi) may clear the decks for the launch of a new asset class—aimed at bridging the gap between mutual funds (MFs) and portfolio management services (PMS)—along with the MF Lite framework for passive fund h")
